Ambalal Sarabhai Enterprises Limited

Equities

AMBALALSA6

INE432A01017

Pharmaceuticals

Delayed Bombay S.E. 05:30:04 2024-05-08 am EDT 5-day change 1st Jan Change
46.7 INR +8.25% Intraday chart for Ambalal Sarabhai Enterprises Limited +1.84% +23.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ambalal Sarabhai Enterprises' CFO Resigns MT
Ambalal Sarabhai Enterprises Limited Announces Change in Directorate, Effective 1st April, 2024 CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Ambalal Sarabhai Enterprises Limited Announces Executive Changes CI
Ambalal Sarabhai Enterprises Limited Appoints Disha Mahesh Punjani as Company Secretary and Compliance Officer CI
Ambalal Sarabhai Enterprises Limited Announces Resignation of Damodar H. Sejpal as Company Secretary and Compliance Officer, Effective October 8, 2023 CI
Ambalal Sarabhai Enterprises Limited Appoints Mr. Brijesh Khandelwal as Additional Independent Director CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Ambalal Sarabhai's Arm Begins Operations at New Vadodara, India Unit MT
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Ambalal Sarabha Unit's JV Gets Indian Drug Regulator's Nod to Market Hepatitis C Viral Load Kit MT
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Ambalal Sarabhai Enterprises : Unit's Joint Venture Gets Indian Drug Regulator's Nod for Dengue Test Kit MT
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Ambalal Sarabhai Enterprises' : Consolidated Profit Climbs in Fiscal Q4 MT
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Ambalal Sarabhai Enterprises : Unit Boost Manufacturing Capacity of Antifungal Antibiotic MT
Ambalal Sarabhai Enterprises : Transfers Stake in Subsidiary to Another Unit Asence Pharma MT
Ambalal Sarabhai Enterprises : JV Secures Regulatory Approval in India for Chikungunya Virus Test Kit MT
Cosara Diagnostics Private Limited, A Joint Venture of A Subsidiary of Ambalal Sarabhai Enterprises Limited Has Received Cdsc License to Manufacture Saragene@Chikungunya Virus Test Kit CI
Ambalal Sarabhai Enterprises Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Chart Ambalal Sarabhai Enterprises Limited
More charts
Ambalal Sarabhai Enterprises Limited is an India-based company that is engaged in the business of manufacturing pharmaceuticals and electronics. The Company's segments include Pharmaceuticals and Electronics. Asence Inc., a wholly owned subsidiary of the Company, specializes in the supply of pharmaceutical preparation (finished dosage forms and active pharmaceutical ingredients) to the international markets. Its subsidiary, Sarabhai Chemicals (India) Private Limited, offers products in oncology, infertility and Uro-gynaec areas. Its wholly owned subsidiary, Suvik Hitek Private Limited, is engaged in manufacturing pharmaceutical products and marketing generics and veterinary products in the domestic market. Its subsidiary, Systronics (India) Limited, is a manufacturer of analytical and test and measuring instruments distributing its products across India. Its other subsidiaries include Synbiotics Limited, Asence Pharma Private Limited, and Sarabhai M Chemicals Limited, among others.
More about the company
  1. Stock Market
  2. Equities
  3. AMBALALSA6 Stock
  4. News Ambalal Sarabhai Enterprises Limited
  5. Ambalal Sarabhai Enterprises : JV Secures Regulatory Approval in India for Chikungunya Virus Test Kit
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW